MAPK3 and cystic fibrosis: In detail, a naringin‐leucine (N‐Leu) powder (obtained by spray‐drying an aqueous solution of leucine and naringin in H2O:EtOH) dissolved in the cell culture medium and immediately administered to both CF and normal bronchial epithelial cells at a concentration of 30 μM reduced the hyperinflammatory status in cystic fibrosis cell lines via inhibiting the expression levels of IKKα, IKKβ, NF‐κB, and phosphorylation of ERK1/2 kinase in CF airway bronchial epithelial cells.